Skip to main content

Table 3 Clinical outcomes

From: Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

Response Assessment Vaccine N = 10 DD + Vaccine N = 7 All N = 17
PR 1 (10 %) 0 1 (6 %)
SD 4 (40 %) 4 (57 %) 8 (47 %)
PD 5 (50 %) 3 (43 %) 8 (47 %)
Time to Progression 4.4 months 4.9 months 4.6 months
  1. DD denileukin diftitox, PD progressive disease, PR partial response, SD stable disease